CIGB-300 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CIGB-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CIGB-300 (P15-Tat) is under investigation for the treatment of adenocarcinoma of the Coronavirus disease 2019 (COVID-19), cervix, squamous cell carcinoma of the cervix, acute myeloid leukemia, and myelodysplastic syndrome and lung cancer. It is a synthetic peptide administered through intravenous and intralesional injection. It acts by targeting casein kinase 2. It was also under development for the treatment of genital warts, solid tumor and chronic lymphocytic leukemia (CLL).
Center for Genetic Engineering and Biotechnology overview
Center for Genetic Engineering and Biotechnology (CIGB) is a biotechnology company that investigates, develops, produces and markets novel biotechnological applications, therapeutic and diagnostic biopharmaceutical products, for the biomedical, agricultural and industrial sectors. CIGB is headquartered in Cuba.
For a complete picture of CIGB-300’s drug-specific PTSR and LoA scores, buy the report here.